Parathyroid hormone: complete guide

Parathyroid hormone is an 84-amino-acid peptide hormone, approved by FDA as Natpara in 2015 and since discontinued. This guide covers its structure, mechanism, trial and warnings.

Complete guide6 min read

Key takeaway

FDA approved Natpara (parathyroid hormone) on January 23, 2015. The label describes an 84-amino-acid hormone weighing 9,425 daltons. In the pivotal trial, 54.8% of Natpara patients met the response goal, versus 2.5% on placebo. Takeda stopped global manufacturing at the end of 2024, and its U.S. special use program closed on December 31, 2025.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Natpara on January 23, 2015.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited1 in this article · 1 across 1 article on Parathyroid hormone
Related productsIncretin analogs

Parathyroid hormone (PTH) is the 84-amino-acid hormone the parathyroid glands use to keep blood calcium in range. A recombinant copy was approved in the United States as Natpara, and its maker has since stopped manufacturing it. This guide covers its structure, mechanism, labeled use, pivotal trial, warnings and supply history. Sources were checked on November 17, 2026.

Quick answer: Parathyroid hormone is a natural peptide hormone that raises blood calcium. Its recombinant form, Natpara, was approved as an add-on to calcium and vitamin D in hypoparathyroidism. The label carries a boxed warning about a potential risk of osteosarcoma, a bone cancer seen in rats. Takeda has discontinued Natpara.

Vitrapep does not sell parathyroid hormone; this page is a reference summary of published research and regulatory information.

What is parathyroid hormone?

PTH is made by the parathyroid glands. The Natpara label states that “parathyroid hormone has 84 amino acids and a molecular weight of 9425 daltons.” The drug’s active ingredient was “produced by recombinant DNA technology using a modified strain of Escherichia coli” (Natpara label, 2022).

A single chain of 84 amino acids sits at the border between a long peptide and a small protein. Our guides to peptides versus proteins and peptide hormones explain the terms. Some approved drugs use only part of the chain. Teriparatide (Forteo) matches the first 34 amino acids, called PTH(1-34) (Forteo label, 2026). The slow-release prodrug palopegteriparatide releases the same fragment (Yorvipath label, 2026).

Drugs@FDA lists the original approval of Natpara (BLA 125511) on January 23, 2015, to NPS Pharms Inc (Drugs@FDA). The latest label posted there is from April 2022, issued by Shire-NPS Pharmaceuticals, a Takeda company.

Table 1

Parathyroid hormone: key facts

Fact Detail
Structure type Single-chain polypeptide of 84 amino acids; recombinant, made in E. coli
Class Parathyroid hormone (calcium-regulating hormone)
Molecular formula Not given in the Natpara label; no PubChem compound record found
Molecular weight 9,425 daltons (per label)
First FDA approval January 23, 2015 (Natpara, BLA 125511)
Brand names (US) Natpara (Takeda; manufacturing discontinued end of 2024)

How does parathyroid hormone work?

The label explains that PTH “raises serum calcium by increasing renal tubular calcium reabsorption, increasing intestinal calcium absorption.” It also acts “by increasing bone turnover which releases calcium into the circulation.” The gut effect works through vitamin D. PTH helps convert 25-OH vitamin D into its active form, 1,25-OH2 vitamin D (Natpara label, 2022).

In plain terms, PTH pulls calcium in from three places: the kidneys, the gut and bone. In hypoparathyroidism, too little PTH is made, so blood calcium falls. Calcimimetics such as etelcalcetide do the reverse job, lowering PTH when it runs too high.

What is parathyroid hormone approved for?

The Natpara label calls it “a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.”

It lists three limits of use:

  • Because of the potential risk of osteosarcoma, it is recommended only for patients who cannot be well-controlled on calcium supplements and active vitamin D alone.
  • It was not studied in hypoparathyroidism caused by calcium-sensing receptor mutations.
  • It was not studied in acute post-surgical hypoparathyroidism.

What did the key trials show?

REPLACE. The pivotal human trial was a 24-week, randomized, double-blind, placebo-controlled phase 3 study in adults with established hypoparathyroidism. Patients were assigned two to one to Natpara or placebo. A responder had to cut both active vitamin D and calcium supplements by at least half while keeping calcium in a set range.

The label reports that 54.8% (46 of 84) of Natpara patients met that goal. On placebo, 2.5% (1 of 40) did (p < 0.001). The published report randomized 134 patients and found 53% versus 2% (P < 0.0001) (Mannstadt et al., 2013). Serious adverse events occurred in 11% of the active group and 9% of the placebo group. The registry record is NCT00732615.

What side effects does the label list?

The Natpara label carries a boxed warning titled “Potential risk of osteosarcoma.” It states that in male and female rats, PTH “caused an increase in the incidence of osteosarcoma (a malignant bone tumor).” The label adds that a risk to humans could not be excluded. Because of this, Natpara was available only through a restricted program called the Natpara REMS.

The most common reactions, each above 10%, were paresthesia, hypocalcemia, headache, hypercalcemia, nausea, hypoesthesia, diarrhea, vomiting, arthralgia, hypercalciuria and pain in extremity. Some trial rates, Natpara versus placebo:

  • Paresthesia (tingling): 31% versus 25%
  • Hypocalcemia: 27% versus 23%
  • Headache: 25% versus 23%
  • Hypercalcemia: 19% versus 3%
  • Diarrhea and vomiting: 12% each versus 3% and 0%

Other warnings cover severe hypercalcemia, severe hypocalcemia when treatment is interrupted, digoxin toxicity and hypersensitivity (Natpara label, 2022).

What is parathyroid hormone’s regulatory status, and how is it used in research?

Natpara was a prescription biologic. On September 5, 2019, Takeda recalled all U.S. Natpara for the “potential presence of rubber particulate.” The recall notice warned that stopping Natpara abruptly “can cause a sharp decrease in blood calcium levels (severe hypocalcemia)” (FDA, 2019).

On October 4, 2022, Takeda said it would stop making Natpara globally at the end of 2024. It cited “unresolved supply issues that are specific to the product” and said it “will not re-commercialize NATPARA in the U.S.” (Takeda, 2022). A final notice dated December 2, 2025, posted by FDA, said the U.S. Special Use Program would close on December 31, 2025. No shipments would follow (Takeda, 2025).

The discontinuation was a supply decision, not a safety withdrawal of the approval. Drugs@FDA still listed BLA 125511 as a prescription product when we checked. The research summarized here is clinical, in human patients.

Frequently asked questions about parathyroid hormone

Is parathyroid hormone a peptide?

Yes. It is a single chain of 84 amino acids, large enough that it is sometimes called a small protein.

When was parathyroid hormone approved as a drug?

Drugs@FDA lists the original approval of Natpara on January 23, 2015.

Is Natpara still available in the United States?

No longer through routine supply. Takeda ended manufacturing at the end of 2024, and its special use program closed on December 31, 2025.

How is it different from teriparatide?

Natpara is the full 84-amino-acid hormone. Teriparatide is only the first 34 amino acids. See our teriparatide guide.

Why did Natpara have a boxed warning?

Rats given parathyroid hormone developed more osteosarcoma, and the label states a risk to humans could not be excluded.

What to know now

  • Structure: 84-amino-acid polypeptide hormone; 9,425 daltons; recombinant in E. coli.
  • Approval: Natpara, January 23, 2015 (BLA 125511).
  • Label use: add-on to calcium and vitamin D to control hypocalcemia in hypoparathyroidism.
  • Evidence: REPLACE responders 54.8% versus 2.5% on placebo.
  • Safety: boxed warning for potential osteosarcoma risk; REMS program.
  • Supply: recalled in 2019; manufacturing ended end of 2024; U.S. special use program closed December 31, 2025.

What we’re watching

Any change to the Natpara listing on Drugs@FDA. Label updates for the PTH(1-34) prodrug Yorvipath, last revised in October 2026. Related guides: palopegteriparatide, teriparatide and abaloparatide.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Shire-NPS Pharmaceuticals 2022, NATPARA (parathyroid hormone) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: BLA 125511 (NATPARA) . Retrieved November 17, Drugs@FDA: BLA 125511 (NATPARA); Mannstadt 2013, The Lancet Diabetes & Endocrinology, 1; Shire 2008, Use of NPSP558 in the treatment of hypoparathyroidism (REPLACE); U.S. Food and Drug Administration 2019; Takeda 2022; Takeda Pharmaceuticals U.S.A 2025; Eli Lilly and Company 2026, FORTEO (teriparatide) prescribing information; Ascendis Pharma 2026, YORVIPATH (palopegteriparatide) prescribing information. All 9 citations

Back to the research library

References

  1. Shire-NPS Pharmaceuticals, Inc. (2022). NATPARA (parathyroid hormone) prescribing information (revised 04/2022). Drugs@FDA, U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125511s028lbl.pdf
  2. U.S. Food and Drug Administration. Drugs@FDA: BLA 125511 (NATPARA). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125511
  3. Mannstadt, M., et al. (2013). Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): A double-blind, placebo-controlled, randomised, phase 3 study. The Lancet Diabetes & Endocrinology, 1(4), 275-283. https://doi.org/10.1016/S2213-8587(13)70106-2
  4. Shire. (2008). Use of NPSP558 in the treatment of hypoparathyroidism (REPLACE) (ClinicalTrials.gov ID NCT00732615). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00732615
  5. U.S. Food and Drug Administration. (2019, September 5). Takeda issues US recall of NATPARA (parathyroid hormone) for injection due to the potential for rubber particulate. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/takeda-issues-us-recall-natparar-parathyroid-hormone-injection-due-potential-rubber-particulate
  6. Takeda. (2022, October 4). Takeda to discontinue manufacturing of NATPAR/NATPARA for patients with hypoparathyroidism at the end of 2024. https://www.takeda.com/en-us/newsroom/statements/2022/takeda-to-discontinue-manufacturing-of-natpar-natpara/
  7. Takeda Pharmaceuticals U.S.A., Inc. (2025, December 2). Final notice: NATPARA (parathyroid hormone) U.S. Special Use Program closes December 31, 2025. U.S. Food and Drug Administration. https://www.fda.gov/media/189951/download
  8. Eli Lilly and Company. (2026). FORTEO (teriparatide) prescribing information (revised 8/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0
  9. Ascendis Pharma, Endocrinology, Inc. (2026). YORVIPATH (palopegteriparatide) prescribing information (revised 10/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1fa23fd-c434-443e-9a17-5750578c8602